Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

Aerovate Therapeutics, a US-based pulmonary disease treatment developer backed by spinout-focused venture capital firm Osage University Partners, went public yesterday following an initial public offering that raised more than $121m. The company issued more than 8.68 million shares priced at $14 in its upsized offering on the Nasdaq Global Market, where it has listed under…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.